100 episodes

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

BioCentury This Week BioCentury

    • Science
    • 5.0 • 9 Ratings

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

    Ep. 97 - Buysiders' Picks, plus JPM22 roundup

    Ep. 97 - Buysiders' Picks, plus JPM22 roundup

    • 27 min
    Ep. 96 - Aduhelm, Pazdur, Pharma Digital & '21 Wrap

    Ep. 96 - Aduhelm, Pazdur, Pharma Digital & '21 Wrap

    • 23 min
    Ep. 95 - ASH's New Targets, Avistone & Washington Update

    Ep. 95 - ASH's New Targets, Avistone & Washington Update

    • 19 min
    Ep. 94 - Woodcock's To-Do List, Maraganore's Takeaways & the Distillery

    Ep. 94 - Woodcock's To-Do List, Maraganore's Takeaways & the Distillery

    • 22 min
    Ep. 93 - Omicron's Open Questions, Plus the Business Case for Ultra-rare Diseases

    Ep. 93 - Omicron's Open Questions, Plus the Business Case for Ultra-rare Diseases

    • 19 min
    Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights

    Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights

    • 23 min

Customer Reviews

5.0 out of 5
9 Ratings

9 Ratings

Pretty Kitty 2 ,

Simone Fishburn!!!!

Simone Fishburn is so well spoken and such a tremendous host. Need more of her in our lives !!

Top Podcasts In Science

Hidden Brain
Alie Ward
Bret Weinstein & Heather Heying
Science Friday and WNYC Studios
Exactly Right
Sam Harris

You Might Also Like

Timmerman Report
Morgan Stanley
Goldman Sachs
The New England Journal of Medicine